Evaluation of the cough profile of fosinopril in hypertensive patients with ACE inhibitor-associated cough-A pilot study

F. Wilford Germino, Juan Lastra, Peter Pool, Henry Punzi, Bruce Spinowitz, William Smith, Susan Wallace, Michael Willett, Donna Mills, Jacqueline De Silva, Dennis Cryer

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

To evaluate the cough profile of fosinopril in treated hypertensive patients with active cough associated with angiotensin-converting enzyme (ACE) inhibitors other than fosinopril, a 7-week, prospective, open-label study was undertaken. This consisted of a 1-week treatment with the previous ACE inhibitor, during which ACE inhibitor-associated cough was confirmed, followed by a switch to fosinopril, 10 to 20 mg once daily, for 6 weeks. The cough profiles of 24 men or women with mild to moderate essential hypertension controlled by an ACE inhibitor other than fosinopril, and with active, nonproductive ACE inhibitor-associated cough, were closely monitored. Significant (P < 0.001, paired t test) decreases in cough frequency, severity, and index, and significant (P < 0.03, paired t test) changes in the characteristics of the cough were observed when patients with ACE inhibitor-associated cough were switched over to fosinopril for 6 weeks. This pilot study has demonstrated a significant improvement in the cough symptom profile of patients who had been actively coughing with other ACE inhibitor therapy when switched to fosinopril, and raises the question as to whether the production of cough may vary among ACE inhibitors.

Original languageEnglish (US)
Pages (from-to)469-475
Number of pages7
JournalCurrent Therapeutic Research
Volume54
Issue number5
DOIs
StatePublished - Jan 1 1993

Fingerprint

Fosinopril
Angiotensin-Converting Enzyme Inhibitors
Cough
Enzyme Therapy

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Evaluation of the cough profile of fosinopril in hypertensive patients with ACE inhibitor-associated cough-A pilot study. / Wilford Germino, F.; Lastra, Juan; Pool, Peter; Punzi, Henry; Spinowitz, Bruce; Smith, William; Wallace, Susan; Willett, Michael; Mills, Donna; De Silva, Jacqueline; Cryer, Dennis.

In: Current Therapeutic Research, Vol. 54, No. 5, 01.01.1993, p. 469-475.

Research output: Contribution to journalArticle

Wilford Germino, F, Lastra, J, Pool, P, Punzi, H, Spinowitz, B, Smith, W, Wallace, S, Willett, M, Mills, D, De Silva, J & Cryer, D 1993, 'Evaluation of the cough profile of fosinopril in hypertensive patients with ACE inhibitor-associated cough-A pilot study', Current Therapeutic Research, vol. 54, no. 5, pp. 469-475. https://doi.org/10.1016/S0011-393X(05)80665-4
Wilford Germino, F. ; Lastra, Juan ; Pool, Peter ; Punzi, Henry ; Spinowitz, Bruce ; Smith, William ; Wallace, Susan ; Willett, Michael ; Mills, Donna ; De Silva, Jacqueline ; Cryer, Dennis. / Evaluation of the cough profile of fosinopril in hypertensive patients with ACE inhibitor-associated cough-A pilot study. In: Current Therapeutic Research. 1993 ; Vol. 54, No. 5. pp. 469-475.
@article{852a1139f1ec422e858a77a3dbd7ea44,
title = "Evaluation of the cough profile of fosinopril in hypertensive patients with ACE inhibitor-associated cough-A pilot study",
abstract = "To evaluate the cough profile of fosinopril in treated hypertensive patients with active cough associated with angiotensin-converting enzyme (ACE) inhibitors other than fosinopril, a 7-week, prospective, open-label study was undertaken. This consisted of a 1-week treatment with the previous ACE inhibitor, during which ACE inhibitor-associated cough was confirmed, followed by a switch to fosinopril, 10 to 20 mg once daily, for 6 weeks. The cough profiles of 24 men or women with mild to moderate essential hypertension controlled by an ACE inhibitor other than fosinopril, and with active, nonproductive ACE inhibitor-associated cough, were closely monitored. Significant (P < 0.001, paired t test) decreases in cough frequency, severity, and index, and significant (P < 0.03, paired t test) changes in the characteristics of the cough were observed when patients with ACE inhibitor-associated cough were switched over to fosinopril for 6 weeks. This pilot study has demonstrated a significant improvement in the cough symptom profile of patients who had been actively coughing with other ACE inhibitor therapy when switched to fosinopril, and raises the question as to whether the production of cough may vary among ACE inhibitors.",
author = "{Wilford Germino}, F. and Juan Lastra and Peter Pool and Henry Punzi and Bruce Spinowitz and William Smith and Susan Wallace and Michael Willett and Donna Mills and {De Silva}, Jacqueline and Dennis Cryer",
year = "1993",
month = "1",
day = "1",
doi = "10.1016/S0011-393X(05)80665-4",
language = "English (US)",
volume = "54",
pages = "469--475",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "5",

}

TY - JOUR

T1 - Evaluation of the cough profile of fosinopril in hypertensive patients with ACE inhibitor-associated cough-A pilot study

AU - Wilford Germino, F.

AU - Lastra, Juan

AU - Pool, Peter

AU - Punzi, Henry

AU - Spinowitz, Bruce

AU - Smith, William

AU - Wallace, Susan

AU - Willett, Michael

AU - Mills, Donna

AU - De Silva, Jacqueline

AU - Cryer, Dennis

PY - 1993/1/1

Y1 - 1993/1/1

N2 - To evaluate the cough profile of fosinopril in treated hypertensive patients with active cough associated with angiotensin-converting enzyme (ACE) inhibitors other than fosinopril, a 7-week, prospective, open-label study was undertaken. This consisted of a 1-week treatment with the previous ACE inhibitor, during which ACE inhibitor-associated cough was confirmed, followed by a switch to fosinopril, 10 to 20 mg once daily, for 6 weeks. The cough profiles of 24 men or women with mild to moderate essential hypertension controlled by an ACE inhibitor other than fosinopril, and with active, nonproductive ACE inhibitor-associated cough, were closely monitored. Significant (P < 0.001, paired t test) decreases in cough frequency, severity, and index, and significant (P < 0.03, paired t test) changes in the characteristics of the cough were observed when patients with ACE inhibitor-associated cough were switched over to fosinopril for 6 weeks. This pilot study has demonstrated a significant improvement in the cough symptom profile of patients who had been actively coughing with other ACE inhibitor therapy when switched to fosinopril, and raises the question as to whether the production of cough may vary among ACE inhibitors.

AB - To evaluate the cough profile of fosinopril in treated hypertensive patients with active cough associated with angiotensin-converting enzyme (ACE) inhibitors other than fosinopril, a 7-week, prospective, open-label study was undertaken. This consisted of a 1-week treatment with the previous ACE inhibitor, during which ACE inhibitor-associated cough was confirmed, followed by a switch to fosinopril, 10 to 20 mg once daily, for 6 weeks. The cough profiles of 24 men or women with mild to moderate essential hypertension controlled by an ACE inhibitor other than fosinopril, and with active, nonproductive ACE inhibitor-associated cough, were closely monitored. Significant (P < 0.001, paired t test) decreases in cough frequency, severity, and index, and significant (P < 0.03, paired t test) changes in the characteristics of the cough were observed when patients with ACE inhibitor-associated cough were switched over to fosinopril for 6 weeks. This pilot study has demonstrated a significant improvement in the cough symptom profile of patients who had been actively coughing with other ACE inhibitor therapy when switched to fosinopril, and raises the question as to whether the production of cough may vary among ACE inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0027491046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027491046&partnerID=8YFLogxK

U2 - 10.1016/S0011-393X(05)80665-4

DO - 10.1016/S0011-393X(05)80665-4

M3 - Article

VL - 54

SP - 469

EP - 475

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 5

ER -